UK-recruiting trials from ClinicalTrials.gov — updated daily. Filter by therapeutic area.
The primary purpose of Study INZ701-104 (the ENERGY study) is to assess the safety and tolerability of INZ-701 in infants with ENPP1 Deficiency or with ABCC6 Deficiency.
Sponsor: Inozyme Pharma
The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC).…
Sponsor: Merck Sharp & Dohme LLC
The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI…
Sponsor: Amgen
ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply…
Sponsor: Accession Therapeutics Limited
Cancer is one of the leading causes of mortality worldwide and is responsible for an estimated 9.6 million deaths yearly. Cancer-related deaths can be reduced if patients are diagnosed and…
Sponsor: Imperial College London
The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic…
Sponsor: JC Medical, Inc., an affiliate of Edwards Lifesciences LLC
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia (HeFH) or Premature Coronary Artery Disease (CAD)…
Sponsor: Verve Therapeutics, Inc.
Individuals attending the hospital to undergo operations are at risk of developing blood clots in the legs, known as deep vein thrombosis (DVT). A clot in the leg can cause…
Sponsor: Imperial College London
This study will enroll male and female subjects who are 18 years of age or older with Eosinophilic Granulomatosis With Polyangiitis.
Sponsor: NS Pharma, Inc.
This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus…
Sponsor: European Myeloma Network B.V.
Get weekly clinical updates — guidelines, trials, MHRA alerts — delivered to your inbox. Free for verified HCPs.
By registering you confirm you are a healthcare professional. No spam. Unsubscribe anytime.